Pursuing a Pharmaceutical Distribution Model Aligned with Changes in Market Structure
First written in FY2022. 5 of 7 entries say "Restated". Latest entry: FY2026.
1 other company's latest entry also says "Restated".
- FY2026RestatedAnnual report
「• Taking the lead in implementing the Guidelines for Improving Distribution and thoroughly managing contribution profit / • Establishing an efficient and effective delivery system suited to the characteristics of urban and regional areas」
For a distribution model aligned with the market structure and regional characteristics, the Group continues to pursue contribution profit management and region-specific delivery systems as initiatives. - FY2025AdvancedAnnual report
「• Establishing an efficient and effective delivery system suited to the characteristics of urban and regional areas / • Taking the lead in implementing the Guidelines for Improving Distribution and thoroughly managing contribution profit」
For the pharmaceutical distribution model aligned with the market structure, the Group identifies delivery systems tailored to regional characteristics, the Guidelines for Improving Distribution, and contribution profit management as specific initiatives. - FY2024-Q3RestatedAnnual report
「Under this medium-term management plan, the following were established as practical priorities, and initiatives are being undertaken to achieve them: “1. Pursuing a pharmaceutical distribution model aligned with structural changes in the market and market characteristics,” “2. Evolving the distribution and marketing model in line with advances in healthcare DX,” and “3. Advancing group management in line with the Prime Market.”」
The Group continues to pursue a pharmaceutical distribution model aligned with the market structure and market characteristics as an initiative under the Fifth Medium-Term Management Plan. - FY2024-Q2RestatedAnnual report
「Under this medium-term management plan, the following were established as practical priorities: “1. Pursuing a pharmaceutical distribution model aligned with structural changes in the market and market characteristics,” “2. Evolving the distribution and marketing model in line with advances in healthcare DX,” and “3. Advancing group management in line with the Prime Market.”」
The Group continues to pursue a pharmaceutical distribution model aligned with the market structure and market characteristics as an initiative under the Fifth Medium-Term Management Plan. - FY2024-Q1RestatedAnnual report
「Under this Medium-Term Management Plan, as an initiative: "1. Pursuing a pharmaceutical distribution model aligned with structural changes in the market and market characteristics"」
The Group continues to pursue a pharmaceutical distribution model aligned with the market structure and market characteristics as an initiative under the Fifth Medium-Term Management Plan. - FY2023-Q1RestatedAnnual report
「As an initiative: "1. Pursuing a pharmaceutical distribution model aligned with structural changes in the market and market characteristics"」
The Group is reaffirming the pursuit of a pharmaceutical distribution model aligned with the market structure and market characteristics as an initiative under the Fifth Medium-Term Management Plan. - FY2022First statedAnnual report
「Medium-Term Vision: "Innovating the business model with the next generation in mind" 1. Pursuing a pharmaceutical distribution model aligned with structural changes in the market and market characteristics」
As the first pillar of the Fifth Medium-Term Management Plan, the Group has stated its policy of pursuing a distribution model suited to the market structure and market characteristics.